CPRX Catalyst Pharmaceuticals Inc.

4.04
+0.06  (+2%)
Previous Close 3.98
Open 3.97
Price To Book 5.32
Market Cap 416,310,013
Shares 103,047,033
Volume 876,750
Short Ratio
Av. Daily Volume 2,625,923
Stock charts supplied by TradingView

NewsSee all news

  1. Catalyst Pharmaceuticals Pre-Announces Estimated Firdapse® Revenues and Provides Updates on Advancement of Clinical Development Programs

    - Firdapse 2019 Net Product Revenues Expected to be Approximately $102 Million - Anticipates Full Year 2020 Firdapse Net Product Revenues to be in the Range of $135 million to $155 million - MuSK-MG Clinical Trial Has

  2. Catalyst Pharmaceuticals to Participate in the Piper Jaffray 31st Annual Healthcare Conference

    CORAL GABLES, Fla., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies

  3. Catalyst Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    - Firdapse® Launch Momentum Continues with Q3 Net Revenues of $30.9 Million -Third Quarter GAAP Net Income of $13.6 Million -Catalyst Provides Net Revenue Guidance – Approximately $100 Million for FY 2019 and range of

  4. Catalyst Pharmaceuticals to Hold Third Quarter 2019 Financial Results Conference Call and Webcast on Wednesday, November 13th, 2019

    CORAL GABLES, Fla., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (NASDAQ:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with

  5. Catalyst Pharmaceuticals Announces Top-Line Results of CMS-001, a Phase 3 Trial of Firdapse® (Amifampridine Phosphate) in Patients with Congenital Myasthenic Syndromes (CMS)

    CMS-001 trial is the first and only double-blinded, placebo-controlled study ever conducted in genetically confirmed CMS patients Results in full population across all tested subtypes of CMS did not achieve

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data due 1H 2020.
Firdapse
Spinal Muscular Atrophy (SMA) Type 3
Phase 3 data due 1H 2020.
Firdapse
MuSK-antibody positive myasthenia gravis (MuSK-MG)
Phase 3 trial did not meet primary endpoint - October 30, 2019.
Firdapse
Congenital Myasthenic Syndromes (CMS)
FDA approval announced November 28, 2018.
Firdapse
Lambert-Easton Myasthenic Syndrome (LEMS)

Latest News

  1. Catalyst Pharmaceuticals Pre-Announces Estimated Firdapse® Revenues and Provides Updates on Advancement of Clinical Development Programs

    - Firdapse 2019 Net Product Revenues Expected to be Approximately $102 Million - Anticipates Full Year 2020 Firdapse Net Product Revenues to be in the Range of $135 million to $155 million - MuSK-MG Clinical Trial Has

  2. Catalyst Pharmaceuticals to Participate in the Piper Jaffray 31st Annual Healthcare Conference

    CORAL GABLES, Fla., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies

  3. Catalyst Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    - Firdapse® Launch Momentum Continues with Q3 Net Revenues of $30.9 Million -Third Quarter GAAP Net Income of $13.6 Million -Catalyst Provides Net Revenue Guidance – Approximately $100 Million for FY 2019 and range of

  4. Catalyst Pharmaceuticals to Hold Third Quarter 2019 Financial Results Conference Call and Webcast on Wednesday, November 13th, 2019

    CORAL GABLES, Fla., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (NASDAQ:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with

  5. Catalyst Pharmaceuticals Announces Top-Line Results of CMS-001, a Phase 3 Trial of Firdapse® (Amifampridine Phosphate) in Patients with Congenital Myasthenic Syndromes (CMS)

    CMS-001 trial is the first and only double-blinded, placebo-controlled study ever conducted in genetically confirmed CMS patients Results in full population across all tested subtypes of CMS did not achieve

  6. Catalyst Pharmaceuticals to Participate in the 2019 Cantor Global Healthcare Conference

    CORAL GABLES, Fla., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (NASDAQ:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with

  7. Catalyst Pharmaceuticals, Inc. Comments on Trading in its Common Stock and on its Capital Resources

    CORAL GABLES, Fla., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) is commenting on today's trading activity in its common stock and on the current state of its capital

  8. Catalyst Pharmaceuticals, Inc. Determines Not to Proceed with Previously Announced Public Offering of Common Stock

    CORAL GABLES, Fla., Sept. 13, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) today announced that it will not conclude the offering of shares of its common stock announced on Wednesday,

  9. Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

    CORAL GABLES, Fla., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) announced today that it has commenced an underwritten public offering of 8.0 million shares of its common stock.

  10. Catalyst Pharmaceuticals to Participate in the 14th Annual Citi Biotech Conference on September 4th, 2019

    CORAL GABLES, Fla., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (NASDAQ:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with